GC Aesthetics®, a medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, initiated a significant multi-center and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant.
This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications.
“By generating high-quality clinical evidence, we aim to provide unparalleled insights into the performance and patient benefits of the PERLE™ implant, setting a new standard for breast implant technology and patient care,” said Chris Brotherston, Head of QA / RA and Clinical Affairs at GC Aesthetics.
PERLE™ is a highly innovative line of smooth opaque breast implants that feature a proprietary surface technology (BioQ™), GCA’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel), plus an enhanced version of the safety features that have underpinned GCA’s long-term excellent safety record.
“PERLE™ is a unique and innovative implant and long-term data on safety and efficacy will aid patients and clinicians to make informed choices with confidence. PERLE™ study involves robust and extensive data collection with a large sample size,” commented Ms Nabila Nasir, Consultant Breast and Oncoplastic Surgeon MBBS, BSc, FRCS.
